Article Text

Download PDFPDF

EP312/#540  Intraperitoneal chemotherapy without bevacizumab versus intravenous chemotherapy plus bevacizumab as frontline therapy in advanced ovarian cancer
  1. Wan Hua Stella Ting,
  2. Hsiao-Feng Wang,
  3. Hui-Hua Chen,
  4. Hsu-Dong Sun,
  5. Ming-Chow Wei and
  6. Sheng-Mou Hsiao
  1. Far Eastern Memorial Hospital, Department of Obstetrics and Gynecology, New Taipei City, Taiwan


Introduction To compare the clinical outcomes between intravenous carboplatin/paclitaxel chemotherapy plus bevacizumab versus intraperitoneal cisplatin/paclitaxel chemotherapy without bevacizumab as the frontline treatment in women with advanced ovarian, fallopian tube and primary peritoneal cancer.

Methods All consecutive women with stage II~IV cancer treated with either frontline intraperitoneal cisplatin/paclitaxel without bevacizumab (IP group) or intravenous carboplatin/paclitaxel with bevacizumab (IVB group) at a tertiary referral center were reviewed.

Results A total of 59 women (IP group, n=44; IVB group, n=15) were reviewed. There was no significant difference in the progression-free survival (median: 33.6 versus 14.8 months, p=0.13). However, overall survival (OS) was significantly higher in the IP group, compared with the IVB group (median: not reached versus 31.7 months, p=0.02; adjusted hazard ratio (HR)=0.35, 95% confidence interval (CI)=0.10 to 1.07, p=0.065, figure 1). Additional predictors for OS include cancer stage and the number of chemotherapy cycles. Besides, the standard dose of 100 mg/m2 cisplatin was a predictor for OS, compared with other intraperitoneal regimens (adjusted HR=0.14, 95% CI=0.02 to 0.87, p=0.03, figure 2).

Conclusion/Implications Intraperitoneal cisplatin/paclitaxel chemotherapy without bevacizumab seems to be better in OS, compared to intravenous carboplatin/paclitaxel chemotherapy with bevacizumab in the frontline treatment of women with advanced ovarian cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.